Summary
VNDA Chart
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025
WASHINGTON , May 16, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in investor meetings at the Mizuho Neuro & Ophthalmology Summit 2025 in New York City on Wednesday, May 21, 2025. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.07 per share a year ago.
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results
Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024 Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024 Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026 Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025 Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025 WASHINGTON , May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new growth phase with multiple commercialized products and a rich innovative pipeline.
Vanda Pharmaceuticals Inc. Dividends
Vanda Pharmaceuticals Inc. Earnings
| 29 Jul 2025 (41 Days) Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | 0.05 Cons. EPS | - EPS |
| 5 Feb 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| 31 Jul 2024 Date | | - Cons. EPS | - EPS |
| 29 Jul 2025 (41 Days) Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | 0.05 Cons. EPS | - EPS |
| 5 Feb 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| 31 Jul 2024 Date | | - Cons. EPS | - EPS |
Vanda Pharmaceuticals Inc. (VNDA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Vanda Pharmaceuticals Inc. ever had a stock split?
Vanda Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Mihael H. Polymeropoulos M.D. CEO | NASDAQ (NMS) Exchange | 921659108 Cusip |
| US Country | 368 Employees | - Last Dividend | - Last Split | 12 Apr 2006 IPO Date |
Overview
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for addressing high unmet medical needs on a global scale. With a focus on conditions that affect sleep-wake disorders, schizophrenia, and a variety of other medical conditions, Vanda Pharmaceuticals seeks to improve the quality of life for patients worldwide. Since its incorporation in 2002, and headquartered in Washington, D.C., the company has made significant strides in bringing novel treatments to the market and continues to expand its robust pipeline of promising therapeutic candidates.
Products and Services
- HETLIOZ (tasimelteon) – Marketed for the treatment of non-24-hour sleep-wake disorders. The pipeline for HETLIOZ includes potential applications for:
- Jet lag disorder
- Insomnia
- Delayed sleep phase disorder
- Sleep disturbances in autism spectrum disorder
- Pediatric Non-24
- Fanapt (iloperidone) oral tablets – Marketed for the treatment of schizophrenia, with ongoing development for:
- Bipolar I disorder
- Parkinson's disease psychosis
- A long-acting injectable (LAI) formulation for schizophrenia
- Tradipitant (VLY-686) – A small molecule neurokinin-1 receptor (NK-1R) antagonist in development for:
- Gastroparesis
- Motion sickness
- Atopic dermatitis
- COVID-19 pneumonia
- VTR-297 – A small molecule histone deacetylase inhibitor being studied for:
- Hematologic malignancies
- Various oncology indications
- VQW-765 – A small molecule nicotinic acetylcholine receptor partial agonist under investigation for:
- Performance anxiety
- Psychiatric disorders
- VHX-896 – An active metabolite of iloperidone in development.
- Antisense Oligonucleotide Molecules – Under investigation for various indications.
- Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators and Inhibitors, including:
- VSJ-110 for the treatment of dry eye and ocular inflammation
- VPO-227 for treating secretory diarrhea disorders such as cholera
Contact Information
